- Influence Mechanism of Serum Free Immunoglobulin Light Chain on Pulmonary Inflammatory Response and Serum Levels of Inflammatory Factors in Patients with Chronic Obstructive Pulmonary Disease:

Cuiying Yin

doi:10.5937/jomb0-49201

Cuiying Yin Third Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou 310000, Zhejiang Province, China

DOI: https://doi.org/10.5937/jomb0-49201

Keywords: Chronic obstructive pulmonary disease; Serum free immunoglobulin light chain; Inflammatory factors; Lung function index

Abstract

Introduction: the pathogenesis of chronic obstructive pulmonary disease (COPD) is not fully understood. This work aimed to demonstrate the role of serum free light chains (sFLC) in the pulmonary inflammatory response of COPD patients and its relationship with serum inflammatory cytokine (IC) levels. Material and methods:eighty subjects were enrolled, including 40 COPD patients (COPD group) and 40 healthy controls (control group). All patients were further rolled into four subgroups regarding the Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging criteria. The serum levels of sFLC and ICs were compared between the two groups, and their correlations with lung function indicators were analyzed. Results: the serum sFLC levels of COPD patients were markedly superior to those of healthy controls. The levels of serum sFLC and ICs (tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-8) gradually increased with the severity of the disease. The levels of ICs were negatively correlated with lung function indicators (FEV1% predicted, FEV1/FVC). Conclusion:these findings suggest that serum sFLC may play a critical role in pulmonary inflammatory response of COPD patients and serve as a potential indicator for evaluating COPD severity and predicting disease progression.

References

1. Huang WQ, Liu XT, Jiang GF, Huang Y. The action and mechanism of action of toll-like receptor 4 (TLR4) on the proliferation and migration of non-small cell lung carcinoma cells. J. Biol. Regul. Homeost. Agents, 2022;36(6):1977–1988.
2. Wang ZZ, Zhou HH, Cheng F, Zhang ZD, Long SH. miR-21 negatively regulates the PTEN-PI3K-Akt-mTOR signaling pathway in crohn’s disease by altering immune tolerance and epithelial-mesenchymal transition. Disc. Med., 2022;33(170):153-66.
3. Agustí A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. N. EngL. J. Med., 2019;381(13):1248-1256.
4. Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N. EngL. J. Med., 2019;381(13):1257-66.
5. Lowe KE, Regan EA, Anzueto A, Austin E, Austin JH, Beaty TH, Benos PV, Benway CJ, Bhatt SP, Bleecker ER, Bodduluri S, Bon J, Boriek AM, Boueiz AR, Bowler RP, Budoff M, Casaburi R, Castaldi PJ, Charbonnier JP, Cho MH, Comellas A, Conrad D, Davis CC, Criner GJ, Curran-Everett D, Curtis JL, DeMeo DL, Diaz AA, Dransfield MT, Dy JG, Fawzy A, Fleming M, Flenaugh EL, Foreman MG, Fortis S, Gebrekristos H, Grant S, Grenier PA, Gu T, Gupta A, Han MK, Hanania NA, Hansel NN, Hayden LP, Hersh CP, Hobbs BD, Hoffman EA, Hogg JC, Hokanson JE, Hoth KF, Hsiao A, Humphries S, Jacobs K, Jacobson FL, Kazerooni EA, Kim V, Kim WJ, Kinney GL, Koegler H, Lutz SM, Lynch DA, MacIntye NR, Make BJ, Marchetti N, Martinez FJ,; Maselli DJ, Mathews AM, McCormack MC, Mcdonald MLN, McEvoy CE, Moll M, Molye SS, Murray S, Nath H, Newell JD, Occhipinti M, Paoletti M, Parekh T, Pistolesi M, Pratte KA, Putcha N, Ragland M, Reinhardt JM, Rennard SI, Rosiello RA, Ross JC, Rossiter HB, Ruczinski I, Estepar RS, Sciurba FC, Sieren JC, Singh H, Soler X, Steiner RM, Strand MJ, Stringer WW, Tal-Singer R, Thomashow B, Sánchez-Ferrero GV, Walsh JW, Wan ES, Washko GR, Wells JM, Wendt CH, Westney G, Wilson A, Wise RA, Yen A, Young K, Yun J, Silverman EK, Crapo, JD. COPDGene® 2019: redefining the diagnosis of chronic obstructive pulmonary disease. Chronic Obstr. Pulm. Dis., 2019;6(5):384.
6. Adeloye D, Song PG, Zhu YJ, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir. Med., 2022;10(5):447-58.
7. Bowerman KL, Rehman SF, Vaughan A, Lachner N, Budden KF, Kim RY, Wood DL, Gellatly SL, Shukla SD, Wood LG. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat. commun., 2020;11(1):5886.
8. Szafran BN, Pinkston R, Perveen Z, Ross MK, Morgan T, Paulsen D B, Penn AL, Kaplan BL, Noël A. Electronic-cigarette vehicles and flavoring affect lung function and immune responses in a murine model. Int. J. Mol. Sci., 2020;21(17):6022.
9. Hewitt RJ, Lloyd CM. Regulation of immune responses by the airway epithelial cell landscape. Nat. Rev. Immunol., 2021;21(6):347-62.
10. Hou J, Sun YC. Role of regulatory T cells in disturbed immune homeostasis in patients with chronic obstructive pulmonary disease. Front. Immunol., 2020;11:723.
11. Finney LJ, Belchamber KB, Fenwick PS, Kemp SV, Edwards MR, Mallia P, Donaldson G, Johnston SL, Donnelly LE, Wedzicha JA. Human rhinovirus impairs the innate immune response to bacteria in alveolar macrophages in chronic obstructive pulmonary disease. Am. J. Res. Critical Care Med., 2019;199(12):1496-507.
12. Wiegman CH, Li F, Ryffel B, Togbe D, Chung KF. Oxidative stress in ozone-induced chronic lung inflammation and emphysema: a facet of chronic obstructive pulmonary disease. Front. immunol., 2020;11:1957.
13. Brassington K, Selemidis S, Bozinovski S, Vlahos R. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease. Clin. Sci., 2019;133(7):885-904.
14. Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am. J. Hematol., 2020;95(7):848-860.
15. Hegen H, Arrambide G, Gnanapavan S, Kaplan B, Khalil M, Saadeh R, Teunissen C, Tumani H, Villar LM, Willrich MAV, Zetterberg H, Deisenhammer F. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement. Mult. Scler. J., 2023;29(2):182-195.
16. Fleming CK, Swarttouw T, de Kat Angelino CM, Jacobs JF, Russcher H. Method comparison of four clinically available assays for serum free light chain analysis. Clin. Chem. Lab. Med. (CCLM), 2019;58(1):85-94.
17. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa L, Fonder A. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 2019;33(2):527-31.
18. Leurs C, Twaalfhoven H, Lissenberg-Witte B, Van Pesch V, Dujmovic I, Drulovic J, Castellazzi M, Bellini T, Pugliatti M, Kuhle J, Villar LM, Alvarez-Cermeno JC, Alvarez-Lafuente R, Hegen H, Deisenhammer F, Walchhofer LM, Thouvenot E, Comabella M, Montalban X, Vecsei L, Rajda C, Galimberti D, Scarpini E, Altintas A, Rejdak K, Frederiksen JL, Pihl-Jensen G, Jensen PEH, Khalil M, Voortman MM, Fazekas F, Saiz A, La Puma D, Vercammen M, Vanopdenbosch L, Uitdehaag BMJ, Killestein J, Bridel C, Teunissen C. Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Mult. Scler. J., 2020;26(8):912-923.
19. Gudowska-Sawczuk M, Moniuszko-Malinowska A, Pączek S, Guziejko K, Chorąży M, Mroczko B. Evaluation of Free Light Chains (FLCs) Synthesis in Response to Exposure to SARS-CoV-2. Int. J. Mol. Sci., 2022;23(19):11589.
20. Singh G, Savage NM, Jillella AP, Bollag RJ. Light chain–predominant multiple myeloma subgroup: impaired renal function correlates with decreased survival. Lab. Med., 2022;53(2):145-148.
21. Wang J, Liu LX, Wang GQ, Mi XG, Yin XX, Shao MT, Fan J, Liu YQ, Zhang L. Predictive value of pdw and pc on the prognosis of patients with advanced non-small cell lung cancer receiving platinum-containing chemotherapy. Acta medica mediterr., 2023;39(2):573-580.
22. Zhao X, Wu YQ. Correlations of silent information regulator of transcription 1 (SIRT1) expression, inflammatory factors, and oxidative stress with pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Med. Sci. Monit., 2021;27:e929046-1.
23. Lin BY, Bai L, Wang SL, Lin H. The association of systemic interleukin 6 and interleukin 10 levels with sarcopenia in elderly patients with chronic obstructive pulmonary disease. Int. J. Gen. Med., 2021;14:5893-902.
24. Huang YB, Jiang BQ, Miao XQ, Ma JD, Wang JN, Ding KK, Chen XJ, Hu QM, Fu FY, Zeng T, Hu JY, Hu BB, Yang DH, Zhang XD. The relationship of lymphocyte to high-density lipoprotein ratio with pulmonary function in COPD. Int. J.Chron. Obstruct. Pulmon. Dis., 2020;3159-3169.
25. Yang TY. Expression Profile of IL-17 in lung tissues of patients with lung cancer and COPD and clinical significance. Cell. Mol. Biol., 2022;68(9):135-9.
26. Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur. Heart J., 2020;41(46):4415-4422.